EU Buys $74 Million Worth of Remdesivir

The European Commission signed a $74 million contract with Gilead Sciences for a supply of  remdesivir for treatment for 30,000 patients with severe COVID-19 over the next few months.

The European Medicines Agency approved remdesivir this month, marketed as Veklury, for treatment of COVID-19 patients with pneumonia requiring supplemental oxygen.

The commission said it plans to procure a further supply of the antiviral to cover additional needs in the future.